8 January 2020 - The PBAC considered 188 submissions in 2019.

In contrast, 195 submissions were considered by the PBAC in 2018.

The 188 submissions yielded 258 outcomes; the recommendation rate was 69%. The rate for the previous year was 67%.

The PBAC considered 40 submissions for a 'new medicine' which yielded 43 outcomes. This includes submissions for a new combination product if at least one of the components was considered to be 'new' (i.e. not listed on the PBS in any formulation). The 40 submissions yielded 14 recommendations (33%).

The PBAC considered 16 submissions for a 'new cancer medicine' which yielded 17 outcomes. The 16 submissions yielded just 4 recommendations (24%).

Looking for more insights? Contact us for a more detailed analysis of PBAC submissions and outcomes from 2019 .